ACOTEC SCIEN.H. DL-00001 - Asset Resilience Ratio
ACOTEC SCIEN.H. DL-00001 (7W3) has an Asset Resilience Ratio of 29.34% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2023–2025)
This chart shows how ACOTEC SCIEN.H. DL-00001's Asset Resilience Ratio has changed over time. See ACOTEC SCIEN.H. DL-00001 leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down ACOTEC SCIEN.H. DL-00001's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of ACOTEC SCIEN.H. DL-00001.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €548.14 Million | 29.34% |
| Total Liquid Assets | €548.14 Million | 29.34% |
Asset Resilience Insights
- Very High Liquidity: ACOTEC SCIEN.H. DL-00001 maintains exceptional liquid asset reserves at 29.34% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
ACOTEC SCIEN.H. DL-00001 Industry Peers by Asset Resilience Ratio
Compare ACOTEC SCIEN.H. DL-00001's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Cochlear Ltd
AU:COH |
Medical Devices | 9.76% |
|
Novocure Ltd
NASDAQ:NVCR |
Medical Devices | 43.72% |
|
Sinocare Inc
SHE:300298 |
Medical Devices | 3.53% |
|
L&C Bio Co. Ltd
KQ:290650 |
Medical Devices | 2.14% |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317 |
Medical Devices | 10.88% |
|
Bactiguard Holding AB (publ)
ST:BACTI-B |
Medical Devices | 8.12% |
|
Oncosil Medical Ltd
AU:OSL |
Medical Devices | 0.00% |
|
Anteris Technologies Global Corp
AU:AVR |
Medical Devices | 33.27% |
Annual Asset Resilience Ratio for ACOTEC SCIEN.H. DL-00001 (2023–2025)
The table below shows the annual Asset Resilience Ratio data for ACOTEC SCIEN.H. DL-00001.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 29.34% | €548.14 Million ≈ $640.84 Million |
€1.87 Billion ≈ $2.18 Billion |
+22.56pp |
| 2024-12-31 | 6.78% | €112.80 Million ≈ $131.88 Million |
€1.66 Billion ≈ $1.94 Billion |
-8.21pp |
| 2023-12-31 | 15.00% | €241.58 Million ≈ $282.43 Million |
€1.61 Billion ≈ $1.88 Billion |
-- |
About ACOTEC SCIEN.H. DL-00001
Acotec Scientific Holdings Limited operates as an interventional medical device company that offers vascular interventional treatment products in Mainland China and internationally. The company's products include AcoArt Orchid & Dhalia, a paclitaxel DCB used to prevent stenosis or occlusion in superficial femoral artery and popliteal artery for the treatment of lower extremity artery disease with… Read more